FHTX FY 2024 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M-33.8% YoY

Gross Profit

$23M100.0% margin

Operating Income

-$103M-454.3% margin

Net Income

-$87M-383.2% margin

EPS (Diluted)

$-1.58

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$101M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$284M

Total Liabilities

$330M

Stockholders' Equity

-$46M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$34M	-33.8%
Gross Profit	$23M	$34M	-33.8%
Operating Income	-$103M	-$108M	+4.8%
Net Income	-$87M	-$98M	+12.0%